Despite several improvements in the diagnosis and management of acute myocardial infarction (AMI) this catastrophic event continues to be a major cause of death in the industrialized world. In the United States nearly 1.5 million people sustain AMI (1). About two-thirds of these people are admitted to coronary intensive care units and only 50% of these patients are managed with a confirmed diagnosis of myocardial infarction (MI) (2). Several landmarks in the diagnosis and management of AMI have contributed to the decrease in the mortality rate (3). These include intracoronary/intravenous thrombolysis, increased use of aspirin, development of interventional approaches such as percutaneous coronary transluminal angioplasty (PTCA), improved pharmacological agents using (3-blockers, nitrates, angiotension-converting enzyme (ACE) inhibitors and newer antithrombotic drugs (4).
Despite several improvements in the diagnosis and management of acute myocardial infarction (AMI) this catastrophic event continues to be a major cause of death in the industrialized world. In the United States nearly 1.5 million people sustain AMI (1) . About two-thirds of these people are admitted to coronary intensive care units and only 50% of these patients are managed with a confirmed diagnosis of myocardial infarction (MI) (2) . Several landmarks in the diagnosis and management of AMI have contributed to the decrease in the mortality rate (3) . These include intracoronary/intravenous thrombolysis, increased use of aspirin, development of interventional approaches such as percutaneous coronary transluminal angioplasty (PTCA), improved pharmacological agents using (3-blockers, nitrates, angiotension-converting enzyme (ACE) inhibitors and newer antithrombotic drugs (4) .
Almost all Mls result from coronary atherosclerosis that is subsequently followed by coronary thrombosis. Progressive vascular changes lead to a significant occlusion (>80%) of the coronary artery but do not result in AMI because of the development of a profound collateral network over time. Several factors contribute to the evolution of atherosclerotic plaques that may rupture abruptly resulting in release of several thrombogenic substances mediating platelet activation, thrombin generation, and fibrinolytic deficit. (Fig. 1 ). The freshly formed thrombus interrupts blood flow and produces ischemic injury of the myocardium eventually leading to myocardial necrosis.
PATHOPHYSIOLOGY OF MYOCARDIAL INFARCTION
Most of the patients who die of a MI exhibit atherosclerotic plaques that are composed of fibrous tissue of varying densities and cellular infiltrates with superimposed thrombus. Platelet-rich thrombi are found on the surfaces of the most advanced atherosclerotic lesions and are characterized by calcified lesions, lipid deposits, necrotic debris, and trapped blood on a fibrous cap. The process of plaque rupture is a complicated event with immunologic and thrombotic activation. Plaque rupture is mediated by such enzymes as collagenase, gelatinase, and stromelysin that degrade components of the interstitial matrix. These enzymes are usually released by the intracellular components of plaque. Several cytokines also contribute to the plaque rupture. Upon rupture thrombogenic substances in particular tissue factor (TF) activates the coagulation process. The activation of coagulation is now understood to be a complex network of proteases controlled by several inhibitors (Fig. 2) . In MI the primary activation of the coagulation process is through the activation of factor VII initiated by TF of ruptured plaque origin. In addition, TF is capable of amplifying the activation of monocyte driven TF release to augment coagulation. Once TF/ factor VII complex is formed it is capable of activating factor X to Xa that converts prothrombin to thrombin. At this stage F1.2 is released. The formed thrombin converts fibrinogen to fibrin resulting in the formation of fibrinopeptide A (FPA). The formed thrombin is also capable of forming complexes with antithrombin III leading to the formation of thrombin-antithrombin III complexes (TAT) . During thrombogenesis in AMI all three of these markers may be increased. The fibrin formed undergoes endogenous lysis resulting in formation of fibrin degra-FIG. 1. Pathophysiology of thrombus formation in the vascular system. Atherosclerotic masking or endothelial injury results in the activation of platelets. Soluble thrombomodulin is present in vascular distress syndrome. Activated platelets mediate several direct or signal transduction-induced processes on other cellular responses. Cellular activation results in the release of various mediators that amplify vascular spasm and the coagulation process. Thus, anaphylotoxins (C3a, C4a, and C5a), superoxides, leukotrienes (LtC4), thromboxane B2 (TxB2), serotonin, platelet factor 3, platelet factor 4, platelet activating factor, endothelin-1, and cytokines play a major role in the overall pathophysiology of myocardial infarction. dation products (FDP). Thus, Fl.2, TAT, FPA, and FDP are suggestive evidence of the thrombogenic process. However, several other markers are generated due to the interaction between platelets and endothelium/subendothelium. This process is depicted in Fig. 3 . Damaged and/or distressed (ischemic) endothelium results in the formation of prothrombogenic substances such as factor XII, thromboxanes, endothelin, TF, and various growth factors. The activated platelets in this millieu release plasminogen activator inhibitor (PAI), von Willebrand factor (vWF), fibrinogen, fibronectin, and heparinase contributing to the amplification of the thrombogenic response in this syndrome. The freshly formed fibrin-rich clot is further stabilized by factor XIIIa by cross-linking fibrin monomers. Thus, it is sometimes difficult to lyse an older clot in an infarcted lesion. Therefore, the process of thrombogenesis is the final event for the occlusion of the coronary artery. This pathologic event was first described by Herrick in 1912 (5) . Not until the introduction of thrombolytic agents was this observation reinforced. Thus the current approach to treat MI is largely due to the fact that a fresh clot is digestable by thrombolytic agents (6) .
Acute MI is now managed in a stepwise manner where the use of anticoagulant, antiplatelet, and thrombolytic drugs play a pivotal role (7) . Anticoagulation followed by thrombolysis is usually the first step in the management of AMI. Because of the age of the coronary thrombus, fibrinolytic deficit, and the presence of other factors resisting thrombolysis PTCA, rotablation, and stenting are also considered. All of these interventional procedures inherently represent an additional thrombotic risk, warranting a clear antithrombotic approach to prevent continual thrombogenesis that may lead to reocclusion. Thus, besides the monitoring of myocardial injury markers such as the cardiac enzymes, troponins, and other markers, the profiling of the activation markers of coagulation and platelets along with the vascular distress markers provide valuable information for a managed approach. Simultaneous measurement of these markers may provide a useful guide for the management of the optimal therapeutic strategy. The activation of coagu- lation results in expression of markers of thrombin generation and its complex formation. The fibrinolytic deficit is detectable by measuring PAI-1, plasminantiplasmin complex, and tissue plasminogen activator (TPA)/PAI complex. The Reperfusion occurring with thrombolysis or angioplasty results in an increase in oxygenation and revitalization of the injured myocardium and a decrease of various markers of thrombogenesis (Table 1 ). This process is not without hazard. It is now known that the process of reperfusion is capable of inflicting injury over and above that attributable to the ischemia due to occlusion (9, 10) . Such an injury results in ventricular arrhyth- mias and myocardial stunning. If the process is continued, the late reperfusion damage may result in necrosis and microvascular injury impairing the collateral perfusion. This may lead to reperfusion injury and produce ischemic damage that may be lethal. Numerous reports have shown that myocardial ischemia and reperfusion injury are acute inflammatory processes in which white blood cells have a primary role (11) . Cell adhesion molecules of the selectin, integrin, and immunoglobulin families are intimately involved in leucocyte adhesion that subsequently leads to myocardial reperfusion injury. During thrombolysis and PTCA the ischemia and reperfusion injury play a key role in converting endothelium into a thrombogenic lesion. This is primarily due to an increase in the expression of P-selectin and intracellular adhesion molecules. This results in neutrophil adherence and the release of procoagulant material (12) (13) (14) . The activated endothelium releases thrombotic mediators such as interleukin-8, platelet activating factor, TF, tumor necrosis factor, and other additional adhesion molecules. Knowledge of these activation processes have resulted in the development of several newer approaches to treat this syndrome. It is clear that the complex pathophysiological event seen in acute coronary syndromes eventually develops into a thrombotic process. Therefore, control of this event is important in reducing the mortality (15) .
LABORATORY CONSIDERATIONS
Until recently, the nature of thrombotic process remained difficult to establish before and after MI. It is now clear that thrombosis is the result of a progressive alteration of the blood and vascular system. Epidemiological studies have clearly shown a relationship between the existence of risk factors leading to blood activation that progressively saturates the body's thromboresistant capacity. This period has been clinically dormant for a long time. Thus, use of the molecular markers of hemostatic activation represent a better approach to identify high-risk patients in whom several of the markers of hemostatic activation guide therapy (16) . During the past few years several methods to evaluate various markers of thrombogenesis have been described (17) (18) (19) (20) (21) (22) (23) (24) (25) . Table 2 depicts a list of various molecular markers of hemostatic alteration that are found in increased circulating amounts during the activation or inhibition of this process. Tissue factor is known to play an important role in the activation of clotting systems, and it is released from various sites due to pathologic processes. Tissue factor is primarily present in the cellular membranes and its levels increase upon tissue damage. Thus, at the site of thrombogenesis, the level of this mediator of thrombogenesis may be increased. Recently, tissue factor pathway inhibitor (TFPI), a specific inhibitor of TF, has been found to play a key role in the control of TF-mediated activation of the clotting process (17) . This Kunitz type of inhibitor is also released during heparin therapy and has a key role in the control of thrombogenesis during acute coronary syndromes. Because of the pathophysiological activation processes in cardiovascular disorders, TFPI is likely to provide important diagnostic information in thrombotic and cardiovascular disorders (18) .
TFPI is a useful indicator of endothelial function as well as of the efficacy of heparin and other glycosaminoglycan therapy. Impaired release of this agent during heparinization may be related to heparin resistance in patients. Information concerning the physiological role of TF is limited, and it is proposed that this factor may be involved in various other processes.
Prothrombin fragment 1.2 (F1.2) is found during the activation of the coagulation process in which factor Xa converts prothrombin into thrombin (19) . Therefore, this marker is a reliable indicator of thrombin generation. Thus, patients with persistent thrombotic events may exhibit high levels of this marker. Furthermore, this marker is decreased during antithrombotic therapy suggesting that anticoagulant drugs are capable of suppressing its formation. Once thrombin is formed, it is capable of complexing with endogenous serine protease inhibitors such as antithrombin III. The TAT III complex readily formed during the thrombotic process circulates in the blood of patients who suffer from thrombotic disorders. However, FPA is formed from the action of thrombin on fibrinogen. Thus, this marker is specific for the action of thrombin on fibrinogen and the formation of fibrin. Fibrinopeptide A is a useful marker of thrombin-mediated conversion of fibrinogen to fibrin and is also elevated in patients who have a hypercoagulable state. Antithrombotic drugs are capable of decreasing the circulating amounts of FPA indicating their therapeutic usefulness.
Tissue plasminogen activator is released from the endothelium and facilitates the digestion of on-site fibrin clots. The impairment of TPA release during fibrinolytic deficit in certain disorders such as diabetes, results in thrombotic complications in these patients. Vascular dysfunction and several drugs also contribute to the deficit of this modulator of fibrinolysis. Plasminogen activator inhibitor is also released from the endothelial cells and is capable of neutralizing the actions of TPA. Plasminogen activator inhibitor levels are increased in many patients suffering from fibrinolytic disorders. Plasmin-a2 antiplasmin (PAP) complex is involved during fibrinolytic activation and fibrinolytic therapy. Patients with disseminated intravascular coagulation and primary fibrinolysis also exhibit increased levels of PAP complex. The Bj3 15-42 related peptides (Bj3 RP) are small peptide cleavage products released by the action of plasmin on fibrinogen and represent a sensitive indicator of fibrinolytic activity. The level of these markers are increased even before any measurable decrease in the fibrinogen level. These markers, therefore, represent a sensitive index of fibrinolytic activation. When fibrinogen and fibrin are exposed to the action of circulating plasmin, the resulting digestion process forms digestion products. The digestion of fibrinogen results in fragments X, Y, D, and E that are collectively known as fibrinogen degradation products (FgDP). However, the digestion of fibrin results in the formation of distinct cleavage products such as the XY, DD, and DY, etc. These products are specific indicators of the formation of fibrin and its digestion by plasmin. D-dimer is a sensitive indicator of the formation of fibrin and its digestion and is commonly used to measure the extent of secondary fibrinolytic disorders. The fibrin degradation products are collectively known as FbDPs. Thus, a profiling of these degradation products can be useful in the differential diagnosis of primary and secondary fibrinolysis.
Platelet factor 4, l3-thromboglobulin (3-TG) and serotonin (5HT) are specific activation products of platelets that are released upon the activation of platelets (20) .
However, thromboxane B2 is generated from the activation of platelets by the transformation of arachidonic acid by the platelet cyclooxygenase enzyme. These products of platelet activation are extremely sensitive markers of arterial thrombotic disorders such as thrombotic stroke, peripheral vascular disorders, and platelet-related thrombotic disorders. These markers are also detectable at high concentrations in patients where platelets are activated due to other disorders (21) . The antiplatelet drugs such as aspirin suppress the release of these markers indicating that the activation of platelets is impaired too.
A metabolite of prostacyclin, namely 6-keto-PGFj 1 (PGF,) is a specific marker of endothelial function and is only synthesized by healthy vascular endothelium. Vascular masking or other plaque covered endothelium fails to produce this marker. Thus, during exercise, the decreased levels of this marker may be indicative of vascular dysfunction. Similarly, TPA is also a marker of vascular function and its release is also impaired in patients with vascular defects. Endothelin (ET) is a peptide marker of endothelial distress. Ischemia and other pathologic conditions result in an increased synthesis of this marker of endothelial distress. Therefore, in patients with vascular dysfunction, this marker is elevated. Angiotensin converting enzymes may also be a marker of vascular damage and is released in patients who suffer from vascular damage and related disorders.
Soluble thrombomodulin (S-TM) is a vessel-specific protein that plays an important role in the neutralization of thrombin and conversion of protein C to protein Ca (22) . Most of the endogenous TM is bound to blood vessels. However, vascular damage results in a leakage (nonbinding) of this protein. Thus, S-TM is increased in plasma. In certain patients with atherosclerotic disease and vasculitis, S-TM is found to be increased. C1esterase inhibitor is an important inhibitor that is consumed during the activation of the complement system. The generated C1-esterase forms complexes and results in the formation of Cj-esterase inhibitor complex. This complex is increased in various thrombotic disorders where the simultaneous activation of the complement cascade takes place. The anaphylatoxins represent the peptide fragments of the C,, C3, and C5 components of the complement system. These cleavage products are formed during immunoactivation and are also present at elevated levels in various thrombotic complications. Contact activation of blood results in the generation of kallikrein, an enzyme that converts kininogens into kinins. Kinins are potent mediators of pain and vasodilation. Kinins can also activate white cells and facilitate their procoagulant actions. Thus, kinins are considered as important markers of hemostatic activation.
Tumor necrosis factor (TNF) is one of the main mediators of pathologic responses during septic shock. It is a product of macrophages and it is known to produce multiple effects on cells, including platelets. In addition, TNF plays a key role in the cellular signaling process and regulates the synthesis of certain mediators of inflammation, necrosis, and activation. Increased circulating levels of TNF are found in patients with thrombotic disorders associated with cancer. Leukotriene C4 is a metabolite of arachidonic acid that is found in the white cells. In thrombotic complications associated with inflammation, this marker of cellular activation is also elevated. Platelet activating factor (PAF) is synthesized by mast cells and increased in circulating blood of patients with mast cell activation. During transplant rejection, the levels of these markers are also increased significantly. Furthermore, in various thrombotic disorders where mast cells are involved, its level is increased.
The antiphospholipid syndrome is now known to be associated with arterial and venous thrombotic disorders (23) . Because of the pathophysiological process, this vascular lipid acquires specific abnormal configurations leading to the generation of IgG, IgA, and IgM types. Individual methods for the quantitation of these antibodies and a collective level of these antiphospholipid antibodies, provide a reliable means of detecting this syndrome. Von Willebrand factor is also increased in various prethrombotic states involving both the arterial and venous systems. This protein is involved in the functionality of platelets. Plasma levels of VWF can be readily measured by using an antigenic or a functional method.
These molecular markers of hemostasis alteration have added a new dimension in the diagnosis and prognosis of thrombotic and vascular disorders (24, 25) .
Quantitation of these markers provides a molecular profile of the pathophysiological events that may be useful in the implementation of appropriate therapeutic ap-proaches for a given disorder. Furthermore, because the generation of these markers takes place at a subclinical level, early diagnosis of a pathophysiological event can be readily made. Table 3 lists the chemical nature and the normal ranges of the molecular markers in various pathologic conditions. These markers are a heterogeneous group of chemicals representing peptides, proteins, lipids, glycoproteins, lipoproteins, and molecular complexes. The circulating amount of these markers at resting stages also represents a wide range. However, most of these markers are present in extremely low amounts (pg-ng/mL). Some of these markers are not present at resting stages and they can only be found during active pathologic states. The circulating half-life of these markers is short unless the pathophysiological event is persistent. It is important to obtain proper blood or tissue fluid samples for their estimation. Proper blood drawing plays a crucial role in the quantitation of the physically relevant levels of these markers. Specific guidelines have been established for the proper collection of biological fluids and storage of these samples for the analysis (26, 27) . Table 4 shows a compilation of the origin of various molecular markers of hemostatic activation and assay methods for their quantitation. These markers are generated from the cellular sites or in blood upon pathophysiological activation. The generation of these markers may be localized as in the case of tumors, MI, or due to such conditions as hypercoagulable state and disseminated intravascular coagulation. Since most of these markers are generated at ng/mL or pg/mL levels, enzyme immunoassays have been useful in their quantitation. The detection limit of immunoassays is within the range of the amounts generated during physiological and/or pathologic activation processes. Furthermore, these immunoassays are highly specific for a given marker and other endogenous substances do not interfere in their quantitation. As listed in Table 4 , the radioimmunoassay (RIA) and enzyme-linked immunosorbent assays (ELISA) can be used for the quantitation of these markers. Several commercially available kits have been introduced and are currently being used in several laboratories (28) . Table 5 depicts a projected list of various molecular markers that are altered during pregnancy-related hypercoagulable state, atherosclerosis and vascular spasm. Pregnancy-related hypercoagulable state may result in venous thrombosis. Thus, thrombin-specific markers such as F1+2, FPA, and fibrin-specific degradation products are elevated. However, during atherosclerosis, platelet activation, vascular dysfunction, and markers of platelets and blood vessels are generated (25) . Thus, platelet factor 4, (3-TG, serotonin, and thromboxane B2 2 may be increased. Endothelin, soluble thrombomodulin, and vWF are also increased, suggesting the vascular dysfunction associated with the atherosclerotic process. The TABLE 
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relative increase in these markers is dependent on several factors. However, these factors may provide crucial information of the pathophysiological process. If proper treatment is followed, the levels of these markers may be proportionately decreased. Thus, these markers may be useful in monitoring the therapeutic effects of antithrombotic drugs.
SPECIFIC LABORATORY STUDIES ON THE DIAGNOSTIC EFFICACY OF MOLECULAR MARKERS OF HEMOSTATIC ACTIVATION
During the past several years many sensitive methods based an newer technologies such as ELISAs have been developed for most of the molecular markers of hemostatic activation (24) . These markers can be readily measured to profile the nature of thrombotic activation processes. Some of the studies described in this section are based on the results obtained on the usefulness of these markers at the Loyola University Medical Center.
A comparison of the effects of ionic and nonionic contrast media on the relative generation of thrombin as measured by TAT complex is shown in Fig. 4 . Blood samples collected at various times show an increased TAT complex level in the group treated with the non-ionic contrast media. Of particular interest is the fact that the TAT complex is generated in patients who have been treated with heparin. Thus, heparinization does not appear to totally inhibit the formation of thrombin and may not be effective in the complete control of thrombosis in certain conditions. An alternate anticoagulant such as recombinant hirudin may be more effective in this situation. Figure 5 shows the results of TPA antigen levels in the same group of patients. In this study, TPA antigen levels were found to be markedly lower in patients treated with nonionic contrast media. Blood samples collected at various times exhibited lower TPA levels. The decreased TPA level and increased generation of thrombin as measured by the quantitation of TAT complex may be related to the observed hypercoagulation response in patients administered nonionic contrast media (29, 30) . Figure 6 shows the data on four groups of patients in which thromboxane B2 levels were measured after stress testing. Markedly elevated levels were observed in patients who exhibited anginal pain during the test. A slight elevation of thromboxane B2 was also noted in patients with spontaneous angina and ST segment elevation (31) . This study shows that thromboxane generation may be related to the activation of platelets during anginal pain. Thus, this marker of platelet activation may be useful in patients who have cardiac problems. Additional markers such as ET and ACE may also be elevated in this syndrome.
Tissue factor pathway inhibitor (TFPI) is an important inhibitor of the coagulation process and is present in plasma at <50 ng/mL levels. However, during heparinization its levels increase markedly (17, 18) . The heparininduced increase in TFPI is dependent on the dosage and route of heparin administration. Other polyelectrolytes also increase the level of TFPI. It is suggested that the degree of heparinization obtained in a given clinical indication may be partly dependent on this mediator. To investigate this process, several groups of plasma samples were analyzed for their TFPI antigen level (32) . Figure 7 shows the circulating levels of the TFPI antigen during various anticoagulant states. During therapeutic anticoagulation, the level of this inhibitor is proportionately increased. The data presented on various activated partial thromboplastin time (aPTT) groups clearly suggests that the prolongation of the aPTT is proportional to the relative increase in TFPI antigen level. However, administration of low molecular weight heparin (LMWH) via subcutaneous route also results in an increase in the TFPI antigen level. However, this increase is not as marked as that observed during therapeutic an-ticoagulation. When larger doses of heparin are given for anticoagulation purposes such as during angioplastic procedures (10,000 U) and cardiac bypass surgery, a massive increase in TFPI antigen level is observed. The data suggests that heparin is capable of mobilizing TFPI . from a vascular site pool. It may be reasonable to propose that the degree of anticoagulation observed after heparinization may be partly dependent on the release of TFPI. Failure to release TFPI after heparin therapy or impaired release of this inhibitor may be the cause of heparin resistance in certain patients. Thus, the measurement of this inhibitor during heparin therapy may be a useful tool to determine the clinical efficacy of heparin and related drugs. However, the relative contributions of the heparin releasable TFPI during therapeutic heparinization is unknown at this time. Figure 8 shows the results of the TFPI levels in some of the patients involved in the ESSENCE trial (33) . In this study a weight-adjusted dosage of LMWH was compared with aspirin for the prevention of coronary syndrome. A LMWH namely, enoxaparin was found to increase the TFPI levels in comparison to the heparintreated and the placebo group. In this study the LMWH group also showed a better clinical outcome. The relevance of the elevated levels of TFPI to the better clinical outcome is not known. However, in additional studies, it In an additional study, unfractionated heparin was compared with a LMWH as an anticoagulant. Individual groups of patients undergoing coronary angioplasty were administered a 10,000 U total dose of heparin or 1 mg/kg weight-adjusted LMWH. Table 6 shows the results of the TFPI antigen levels in these two patient groups at the baseline, during the PTCA procedure, and 4 hours after the completion of the procedure. The unfractionated heparin group and the LMWH group produced an increase in the TFPI level. The relative increase in the TFPI with the LMWH was somewhat lower. The clinical outcomes in both groups were similar. This data show that LMWH can be used to anticoagulate patients during coronary angioplasty procedures. Stenting, rotablation, and other cardiovascular interventional procedures result in an increase in the tissue factor levels. These procedures are usually performed after anticoagulation with heparin.
The anticoagulation with heparin is associated with release of TFPI which can produce the inhibition of tissue factor. Table 7 shows the results on total and free TFPI levels in a group of patients undergoing transrotational coronary atherectomy. In this study TFPI levels were measured prior to and after the procedure. The heparin levels were high in the patients during the procedure. Interestingly a greater than threefold increase in the total TFPI and a greater than tenfold increase free TFPI was noted. Since TFPI is increased during heparinization, free and total TFPI levels were also measured in a longterm treatment study with LMWH. In this study patients were administered heparin during the initial procedure and were maintained on a 80 mg daily administered subcutaneously. The free and total TFPI levels were measured. A marked increase in free TFPI and total TFPI were noted. The relative increase in the free TFPI levels was much higher than the total TFPI. Subsequent studies on long-term treatment also showed that TFPI (free and total) remained at a high level. This persistant increase in the TFPI may be related to the better outcome seen in patients treated with LMWH.
Soluble TM levels have been related to vascular distress (34) . Under normal circumstances TM is bound to endothelial cells and serves as a receptor to thrombin.
However, in pathologic states due to activation of proteases, various molecular forms of TM are cleaved and released into circulation. Figure 9 shows the results of the soluble TM levels in patients who were treated with a LMWH (Certoparin) for 3 months. In comparison to the placebo group, the LMWH and control groups showed much lower levels of soluble TM. Thus, the molecular markers of vascular function may be useful in the study of cardiovascular patients. Figure 10 shows the data on the plasma P-selectin FIG. 4. Thrombin-antithrombin complex (TAT) levels in patients' plasma undergoing coronary angioplasty procedure. Two groups of patients (n = 42) were studied for the TAT levels. One group received an ionic contrast media, Omnipaques. The second group received a nonionic contrast media Angiovists. Blood samples were drawn at the baseline, 10 minutes after heparinization (10,000 U/total), 1 hour, 2 hours, and 3 hours postheparinization. Blood samples were immediately centrifuged and collected plasma was frozen. Thrombin-antithrombin levels were measured in batches using the enzyme immunoassay kit methods from Behring Diagnostic, Marburg, Germany. All results represent a mean t 1 standard deviation of 42 individual patient plasma samples.
level in patients recruited in the PARAT trial. The soluble P-selectin levels in patients treated with certoparin were much lower. The data suggest that patients with coronary syndrome may exhibit platelet activation leading to the release of P-selectin. Thus, P-selectin can be FIG. 5. Tissue plasminogen activator (TPA) antigen levels in patients' plasma undergoing coronary angioplasty procedures. Two groups of patients (n = 42) were studied. The first group received an ionic contrast media, Angiovists. The second group received a nonionic contrast media, Omnipaqueg. Blood samples were drawn at the baseline, 10 minutes after heparinization (10,000 U/total), 1 hour, 2 hours, and 3 hours postheparinization. Blood samples were immediately centrifuged and collected plasma was frozen. Tissue plasminogen activator antigen levels were measured using an enzyme immunoassay method from Diagnostica Stago, Gennevilliers, France. All results represent a mean ± 1 standard deviation of 42 individual patient plasma samples. used as a marker of platelet activation in cardiovascular patients. Fibrinolytic deficit is currently seen in diabetic patients with arterial disorders. In the same group of PTCA patients PAI-1 levels were measured after the conclusion of treatment (Fig. 11 ). The treated group showed a much lower PAI-1 activity than the placebo group. The data shows that LMWH treatment can result in a decrease of the PAI-1 level. Thus, LMWH can partially restore the fibrinolytic function. This may be one factor that contributes to the beneficial effects of LMWH in post-PTCA management.
FIG. 7. A comparison of tissue factor pathway antigen levels using various treatment protocols. Blood samples (25-30) from patients undergoing therapeutic anticoagulation (aPTT > 40 secs), low molecular weight heparin (subcutaneous), during angioplasty and cardiac bypass surgery (during pump room) were collected. Blood was individually centrifuged and plasma frozen at -70°C. Tissue factor pathway inhibitor levels were assayed using an enzyme-linked immunoassay method from American Diagnostica, Greenwich, CT, U.S.A. All results were expressed as a mean t 1 standard deviation. aPTT, activated partial thromboplastin time.
FIG. 8. Tissue factor pathway inhibitor (TFPI) antigen levels in unstable angina patients (ESSENCE study groups) treated with heparin and a LMWH (Enoxaparin). Control represents normal levels of TFPI in healthy volunteers. LMWH, low molecular weight heparin.
The relative role of markers of thrombogenesis in acute coronary syndromes is of major importance. Since the presence of these markers in blood is indicative of an ongoing thrombogenic process that may be related to the failure of therapy or reperfusion injury-related pathogenesis. Since reocclusion and embolization are commonly associated with therapeutic approaches for MI, simultaneous measurement of markers of thrombogenesis can be used in the optimization of the management of MI (FI.21 FPA, TAT complexes). Newer markers such as Pselectin and S-TM may provide useful information on platelet/endothelial interaction.
During the past decade some dramatic developments in the management of MI have taken place. The impact of new antithrombotic drugs in the management of acute coronary syndromes is rather remarkable (35) . The introduction of these drugs has revolutionized the management of acute coronary syndromes and secondary prevention of coronary syndromes. Figure 12 shows a comparison of various anticoagulant and antithrombotic drugs. Besides the conventional anticoagulants such as heparin, aspirin, and oral anticoagulant drugs, many newer drugs have been recently introduce (36). Heparin is now depolymerized to develop LMWH. Synthetic heparin derivatives have also been produced. Through recombinant technology such potent anticoagulants as hirudin are developed. Several antithrombin peptides have also been developed. Tissue factor pathway inhibitor is also produced by recombinant technology. Many newer antiplatelet drugs such as ticlopidine, clopidogrel, and ReoProg have been developed. Unlike heparin these drugs have monotherapeutic effects. The safety and efficacy of these agents is not fully understood and these agents require monitoring.
COST AND TECHNOLOGICAL CONSIDERATIONS
While the profiling of various molecular markers of hemostatic activation provides an useful diagnostic battery of tests, currently the cost of performing these tests is high. Considering the current cost containment approaches in health care, it would be difficult to justify an extensive battery of tests for a given patient to facilitate diagnosis of an acute event. Furthermore, these tests require specialized instruments such as the ELISA systems and radiochemical counters that are not readily available. Since many of these tests are available in kits, quality assurance procedures, standardization, and other performance optimization procedures also add to the cost of the assays. These tests may not be cost-effective in small hospitals with a limited number of test requests. However, in large medical centers and reference laboratories with high volumes, some of these tests can be costeffective. It may be that these tests can be offered by reference laboratories serving area hospitals. However, the turnaround time and interpretation of the available data may be a limiting factor for the optimal use of the information generated. Owing to the rapid progress in this area, several newer molecular markers of hemostatic activation and thrombotic transformation will be continually introduced. However, the implementation of some of these tests requires a useful assessment of the diagnostic validity of the newer tests in a given clinical group. Patients with subclinical and clinical acute coronary syndromes may be evaluated by developing specific marker profiles to initiate therapy. This will help in reducing the overall health care cost and may prove to be useful in the differential diagnosis in a given setting.
The diagnostic usefulness of these markers can also be validated in well-designed clinical trials. While multiple profiling of these markers may be expensive, initial screening can provide reliable data on the diagnostic validity of a select number of analytes that can be correlated with a given disorder. However, despite the introduction of over 24 diagnostic kits for the detection of various hemostatic alterations, a large scale clinical trial to relate their diagnostic value is not available at this TFPI, tissue factor pathway inhibitor; PTCA, percutaneous transluminal coronary angioplasty; LMWH, low molecular weight heparin. Free and total tissue factor pathway inhibitor (TFPI) levels were measured in patients undergoing coronary angioplasty. The initial heparinization was followed by the administration of low molecular weight heparin (LMWH) (Certoparin).
time. Limited data is available on the diagnostic efficacy of some of the markers.
Despite the cost limitations, the application of some of these markers such as the F,.2 fragment, FPA platelet factor 4, and D-dimer have provided useful information for the differential diagnosis of hypercoagulable state and thrombotic response during MI. The thrombotic complications observed during reperfusion injury can also be readily assessed using some of these markers. Unlike the conventional coagulation tests that are only useful in the detection of hypercoagulable state due to a disease or drug, these markers are extremely useful in the diagnosis of hypercoagulable state and subclinical activation or inhibition of the hemostatic system during interventional cardiologic procedures such as stenting and PTCA.
SUMMARY
Anticoagulant therapy has undergone some major developments in recent years. Conventional drugs that produce anticoagulant effects such as heparin and oral an-FIG. 9. Soluble thrombomodulin levels in patients treated with a LMWH prior to coronary angioplasty. Soluble thrombomodulin levels were measured after 3 months of treatment with a LMWH using an ELISA method (Diagnostica Stago, Gennevilliers, France). LMWH, low molecular weight heparin, ELISA, enzymelinked immunosorbent assay. ticoagulants are no longer considered the only candidates for the anticoagulant/antithrombotic management of patients. Recombinant hirudin, glycoproteins IIb/IIIa targeting antibodies, synthetic peptides such as Hirulog@ and efegatran are being tested for their efficacy. These drugs produce their effects at different sites. To monitor their overall effects on the hemostatic system, molecular markers offer a practical and reliable approach. Markers of thrombin generation are useful for the monitoring of antithrombin drugs whereas, the efficacy of antiplatelet drugs can be assessed by monitoring the platelet release products. Furthermore, polytherapy using several anticoagulant and antithrombotic drugs in combination has FIG. 11. PAI-1 levels in patients undergoing angioplasty. Blood samples were drawn at the end of the study and PAI-1 levels were measured using an ELISA method (Diagnostica Stago, Gennevilliers, France). All results represent a mean t one standard deviation. PAI-1 = plasminogen activator inhibitor-1; ELISA, enzyme-linked immunosorbent assay.
FIG. 12. A diagramatic representation of various anticoagulant and antithrombotic drugs. These drugs represent a diverse group of agents that are obtained from natural, synthetic, and recombinant technologies. The mode of action of these drugs varies widely. The safety/efficacy index also varies. Thus the monitoring of these agents is rather significant. been considered. In these situations, the use of molecular markers may also prove to be invaluable.
The introduction of simple technology such as the test strip or particle agglutination methods may be available for the measurement of many of these markers in the near future. This will be useful for ready availability and reduced cost for individual marker testing. Furthermore, this type of technology can be used at bedside, off-site, and in doctor's offices. It is clear that the molecular marker profiling provides useful information on the nature of pathophysiology of a given thrombotic disorder. However, for practical use, a cost-effective and simpler assay-based approach will enhance their use, and these tests will be readily accepted at the laboratory and clinical levels. _____ 
REFERENCES ___

